New diagnostic criteria for multiple sclerosis integrating magnetic resonance image
assessment with clinical and other paraclinical methods were introduced in 2001. The “McDonald …

The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple
sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in …

New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis
of multiple sclerosis. The use of imaging for demonstration of dissemination of central …

Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important
for communication, prognostication, design and recruitment of clinical trials, and treatment …

Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized
monoclonal antibody that selectively depletes CD20+ B cells. Methods In two identical …

Two prior double‐blind, placebo‐controlled, randomized trials demonstrated that glatiramer
acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (…

Background Teriflunomide is a new oral disease-modifying therapy for relapsing forms of
multiple sclerosis. Methods We concluded a randomized trial involving 1088 patients with …

Background Teriflunomide is an oral disease-modifying therapy approved for treatment of
relapsing or relapsing–remitting multiple sclerosis. We aimed to provide further evidence for …

Objective To determine whether glatiramer acetate (GA) slows accumulation of disability in
primary progressive multiple sclerosis. Methods A total of 943 patients with primary …